RxDoctor Payments Data

Lauren Berry, MD

Rheumatology · Green Bay, WINPI 1932660404

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 42.5% of the total.

$1,534in general payments, 2019–2025

Across 45 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$651
  • Mallinckrodt Hospital Products Inc.$264
  • GSK$249
  • Amgen$159
  • Genentech USA, Inc.$41
  • Lilly USA, LLC$39
  • plus $131 from 5 others

What the payments were for

  • Food & beverage$1,534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,534 in reported general payments places this provider in the 65th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$83,981
Medicare patients
56
Services billed
2,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$296,610
RinvoqUpadacitinib12$89,436
Taltz AutoinjectorIxekizumab11$74,853
ActemraTocilizumab13$71,895
Actemra ActpenTocilizumab14$66,684
Enbrel SureclickEtanercept12$65,694
BenlystaBelimumab13$62,250
ForteoTeriparatide19$49,600
Mycophenolate Mofetil18$6,639
Azathioprine15$3,836
Hydroxychloroquine Sulfate83$3,565
MethotrexateMethotrexate Sodium37$777
Famotidine25$740
Prednisone109$734
Colchicine15$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$651$89,43612 claims
GSKBenlysta$249$62,25013 claims
Lilly USA, LLCForteo$39$49,60019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 rheumatology providers in Wisconsin.

Other rheumatology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →